Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855082 | 0.92 | TRPV1 (0.66) | TRPV1TRPV4 | |
| SCHEMBL1857213 | 0.92 | TRPV1 (0.66) | TRPV1TRPV4 | |
| SCHEMBL1858836 | 0.92 | TRPV1 (0.66) | TRPV1TRPV4 | |
| SCHEMBL4613478 | 0.91 | TRPV1 (0.66) | TRPV1TRPV4 | |
| SCHEMBL1856671 | 0.88 | TRPV1 (0.57) | TRPV1TRPV4 | |
| SCHEMBL1859543 | 0.88 | TRPV1 (0.64) | TRPV1TRPV4 | |
| SCHEMBL11041564 | 0.87 | TRPV1 (0.65) | TRPV1TRPV4 | |
| SCHEMBL11041558 | 0.87 | TRPV1 (0.65) | TRPV1TRPV4 | |
| SCHEMBL1865247 | 0.87 | TRPV1 (0.66) | TRPV1TRPV4 | |
| SCHEMBL28757236 | 0.86 | TRPV1 (0.64) | TRPV1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101827585-A | Solid dispersion product containing N-aryl ureido compound | ABBOTT GMBH & CO KG | 2010-09-08 | — | — | CN | claimed |
| EP-2197426-A2 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | Abbott GmbH & Co. KG (DE) | 2010-06-23 | — | — | EP | claimed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | claimed |
| WO-2009050289-A2 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-04-23 | — | — | WO | claimed |
| EP-2017265-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | Abbott Laboratories (US) | 2009-01-21 | — | — | EP | claimed |
| EP-1658269-B1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-22 | — | — | EP | claimed |
| JP-2007500753-A | — | — | 2007-01-18 | — | — | JP | claimed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | claimed |
| US-7015233-B2 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-03-21 | — | — | US | claimed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | claimed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | claimed |
| US-20040254188-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-12-16 | — | — | US | claimed |
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8071762-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-12-06 | — | — | US | disclosed |
| US-8026256-B2 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-09-27 | — | — | US | disclosed |
| US-7015233-B2 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060035934-A1 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBVIE INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20040254188-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035934-A1 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | TRPV1, TRPV2, OPRL1 | TRPV1 1/4885TRPV4 8/4885 |
| US-20040254188-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, OPRL1, TRPV2 | TRPV1 1/4885TRPV4 13/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | TRPV1 2/4885TRPV4 23/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | TRPV1 4781/4885TRPV4 4658/4885 |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | TRPV1 2/4885TRPV4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.